Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that results from the Phase 1/2 study (KL264-01/MK-2870-001) evaluating the novel TROP2 antibody drug conjugate (ADC)...
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant...
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company...
Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren's Contracture
– Conducted under U.S. FDA-cleared IND – Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage biotechnology company, announced the successful...
Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy
– Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of lead...